Role of Statin in Venous Dysfunction in Patients With Venous Thromboembolism Event

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 19, 2019

Primary Completion Date

March 29, 2024

Study Completion Date

May 30, 2025

Conditions
Venous ThromboembolismDyslipidemias
Interventions
DRUG

Rosuvastatin 20mg

Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.

DRUG

Control

Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.

Trial Locations (1)

03722

Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT03988101 - Role of Statin in Venous Dysfunction in Patients With Venous Thromboembolism Event | Biotech Hunter | Biotech Hunter